BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to cures for cancer and other serious diseases, today announced that two-year follow-up data for ...
In a study presented at the 2017 American Society of Clinical Oncology Annual Meeting, researchers at MD Anderson Cancer Center used data on 12,052 elderly patients diagnosed with neuroendocrine ...
A recap of the dapagliflozin data from the DAPA-CKD study and how it relates to reductions in healthcare resource utilization. Robert Toto, MD: What they found was not too surprising because you’d ...
When emergency physicians are faced with limited resources or extreme demand, they need to employ specific strategies to optimize resource utilization and outcomes, according to an article in the ...
BOSTON--(BUSINESS WIRE)--Pear Therapeutics, Inc. (Nasdaq: PEAR), the leader in developing and commercializing software-based medicines, called prescription digital therapeutics (PDTs), today announced ...
First-line therapies analysis in advanced/metastatic urothelial carcinoma: Prognostic insights with propensity score analysis and RNA-seq. Enfortumab vedotin plus pembrolizumab in metastatic ...
Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC). This is an ASCO Meeting Abstract from the 2022 ASCO Genitourinary Cancers Symposium. This ...
Data from patients with NHL treated in Phase 1 investigator-led study of GDA-201 demonstrates median duration of response of 16 months; safety outcomes consistent after two years Poster presentation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results